Etravirine plasma levels in a patient with decompensated liver disease
暂无分享，去创建一个
[1] Amalio Telenti,et al. Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients , 2005, Pharmacogenetics and genomics.
[2] B. Gazzard,et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study , 2004, The Lancet.
[3] M. Lederman,et al. MDR1 Gene Polymorphisms and Phase 1 Viral Decay During HIV‐1 Infection An Adult AIDS Clinical Trials Group Study , 2003, Journal of acquired immune deficiency syndromes.
[4] S. Hammer,et al. Population Pharmacokinetics and Pharmacodynamics of Efavirenz, Nelfinavir, and Indinavir: Adult AIDS Clinical Trial Group Study 398 , 2003, Antimicrobial Agents and Chemotherapy.
[5] R H Levy,et al. Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450. , 1999, Drug metabolism and disposition: the biological fate of chemicals.